Shares of Sionna Therapeutics, Inc. (NASDAQ:SION - Get Free Report) were up 6.8% during trading on Thursday . The stock traded as high as $13.75 and last traded at $13.60. Approximately 19,493 shares were traded during mid-day trading, a decline of 90% from the average daily volume of 186,247 shares. The stock had previously closed at $12.73.
Wall Street Analysts Forecast Growth
Several equities research analysts have issued reports on the stock. TD Cowen started coverage on shares of Sionna Therapeutics in a research report on Tuesday, March 4th. They issued a "buy" rating for the company. Wall Street Zen cut shares of Sionna Therapeutics from a "hold" rating to a "sell" rating in a research report on Thursday, May 22nd. Guggenheim initiated coverage on shares of Sionna Therapeutics in a research report on Tuesday, March 4th. They set a "buy" rating and a $45.00 price target for the company. Finally, Stifel Nicolaus began coverage on shares of Sionna Therapeutics in a research report on Tuesday, March 4th. They issued a "buy" rating and a $32.00 price objective on the stock.
View Our Latest Research Report on Sionna Therapeutics
Sionna Therapeutics Price Performance
The business has a fifty day moving average price of $11.74.
Sionna Therapeutics (NASDAQ:SION - Get Free Report) last released its earnings results on Monday, May 12th. The company reported ($0.62) EPS for the quarter, missing analysts' consensus estimates of ($0.45) by ($0.17).
Institutional Investors Weigh In On Sionna Therapeutics
A number of large investors have recently made changes to their positions in SION. Jennison Associates LLC acquired a new position in shares of Sionna Therapeutics in the first quarter valued at about $8,995,000. TD Asset Management Inc purchased a new stake in Sionna Therapeutics in the first quarter valued at approximately $579,000. Charles Schwab Investment Management Inc. purchased a new stake in Sionna Therapeutics in the first quarter valued at approximately $676,000. CenterBook Partners LP purchased a new position in Sionna Therapeutics during the 1st quarter worth approximately $1,195,000. Finally, Aberdeen Group plc purchased a new position in Sionna Therapeutics during the 1st quarter worth approximately $7,803,000.
About Sionna Therapeutics
(
Get Free Report)
We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.
Recommended Stories
Before you consider Sionna Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sionna Therapeutics wasn't on the list.
While Sionna Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
